Get the latest tech news
The FDA clears the first blood test for diagnosing Alzheimer's disease
Previously, screening required a more invasive PET scan or spinal tap.
Fujirebio Diagnostics' Lumipulse measures the ratio of two proteins that correlate with the presence or absence of Alzheimer's. Previously, patients being screened for Alzheimer's were limited to more invasive options: a PET Scan or spinal tap. Lumipulse is intended for use in clinical settings with patients exhibiting signs of cognitive decline.
Or read this on Endgadget